Evidence map›Paper›PMID 36400933›Full record

ArticleNature metabolism2022

Brown adipose tissue-derived Nrg4 alleviates endothelial inflammation and atherosclerosis in male mice.

Lingfeng Shi, Yixiang Li, Xiaoli Xu, Yangyang Cheng, Biying Meng, Jinling Xu, Lin Xiang, Jiajia Zhang, Kaiyue He, Jiayue Tong and 3 more

RetractedErratum issuedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Nature metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Ablation ofScience (New York, N.Y.) · 2026
    Article
  8. Article
  9. Neuregulin 4 in Insulin Resistance: Mechanisms, Controversies, and Therapeutic Perspectives.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Lingfeng ShiDepartment of Endocrinology, General Hospital of Central Theater Command, Wuhan, China.ORCID http://orcid.org/0000-0002-3115-2520
Yixiang LiDepartment of Hematology and Medical Oncology, School of Medicine, Emory University, Atlanta, GA, USA.
Xiaoli XuDepartment of Endocrinology, General Hospital of Central Theater Command, Wuhan, China.
Yangyang ChengDepartment of Endocrinology, General Hospital of Central Theater Command, Wuhan, China.
Biying MengDepartment of Endocrinology, General Hospital of Central Theater Command, Wuhan, China.
Jinling XuThe First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Lin XiangDepartment of Endocrinology, General Hospital of Central Theater Command, Wuhan, China.
Jiajia ZhangDepartment of Endocrinology, General Hospital of Central Theater Command, Wuhan, China.
Kaiyue HeThe First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Jiayue TongThe First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Junxia ZhangDepartment of Endocrinology, General Hospital of Central Theater Command, Wuhan, China. Zhangjx023@163.com.
Lingwei XiangCenters for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA, USA. Lxiang2@bwh.harvard.edu.
Guangda XiangDepartment of Endocrinology, General Hospital of Central Theater Command, Wuhan, China. Guangda64@hotmail.com.ORCID http://orcid.org/0000-0002-6044-2308
Central Hospital of Wuhan · CNGeneral Hospital of Central Theater CommandSouthern Medical University · CNBrigham and Women's Hospital · USArmy Medical University · CNEmory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brown adipose tissue (BAT) activity contributes to cardiovascular health by its energy-dissipating capacity but how BAT modulates vascular function and atherosclerosis through endocrine mechanisms remains poorly understood. Here we show that BAT-derived neuregulin-4 (Nrg4) ameliorates atherosclerosis in mice. BAT-specific Nrg4 deficiency accelerates vascular inflammation and adhesion responses, endothelial dysfunction and apoptosis and atherosclerosis in male mice. BAT-specific Nrg4 restoration alleviates vascular inflammation and adhesion responses, attenuates leukocyte homing and reduces endothelial injury and atherosclerosis in male mice. In endothelial cells, Nrg4 decreases apoptosis, inflammation and adhesion responses induced by oxidized low-density lipoprotein. Mechanistically, protein kinase B (Akt)-nuclear factor-κB signaling is involved in the beneficial effects of Nrg4 on the endothelium. Taken together, the results reveal Nrg4 as a potential cross-talk factor between BAT and arteries that may serve as a target for atherosclerosis.

Indexed as

Adipose Tissue, BrownAtherosclerosisNeuregulinsAnimalsEndothelial CellsEndotheliumInflammationMaleMiceneuregulin-4Neuregulins

Identifiers

PMID36400933
PMCPMC9684073
OpenAlexW4309410895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.